Eli Lilly And Co (NYSE:LLY) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 16,682,000 shares, an increase of 45.6% from the July 31st total of 11,459,200 shares. Currently, 2.0% of the company’s shares are short sold. Based on an average daily volume of 3,990,000 shares, the short-interest ratio is currently 4.2 days.
In other news, SVP Alfonso G. Zulueta sold 19,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total value of $2,201,745.00. Following the transaction, the senior vice president now owns 38,306 shares of the company’s stock, valued at approximately $4,325,130.46. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Stephen F. Fry sold 9,452 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $115.00, for a total value of $1,086,980.00. Following the completion of the transaction, the senior vice president now directly owns 100,211 shares in the company, valued at approximately $11,524,265. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Prestige Wealth Management Group LLC purchased a new position in shares of Eli Lilly And Co in the 2nd quarter valued at about $34,000. Meridian Wealth Management LLC acquired a new stake in shares of Eli Lilly And Co in the 1st quarter valued at about $38,000. Manchester Financial Inc. acquired a new stake in shares of Eli Lilly And Co in the 2nd quarter valued at about $40,000. Litman Gregory Asset Management LLC acquired a new stake in shares of Eli Lilly And Co in the 2nd quarter valued at about $47,000. Finally, Personal Wealth Partners acquired a new stake in shares of Eli Lilly And Co in the 2nd quarter valued at about $53,000. Institutional investors and hedge funds own 76.78% of the company’s stock.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The business had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the business posted $1.48 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. As a group, sell-side analysts anticipate that Eli Lilly And Co will post 5.72 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were issued a $0.645 dividend. The ex-dividend date was Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.31%. Eli Lilly And Co’s payout ratio is currently 46.49%.
LLY has been the topic of several research analyst reports. Bank of America set a $120.00 price objective on Eli Lilly And Co and gave the company a “neutral” rating in a report on Tuesday. Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Finally, Goldman Sachs Group initiated coverage on Eli Lilly And Co in a report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and a consensus target price of $122.93.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Neutral Rating
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.